In addition to regulating HIF-2α, the VHL E3 ubiquitin ligase has other substrates that may also play important roles in the progression of ccRCC because ccRCC patient samples exhibited differential sensitivity to HIF-2α inhibitors (29–31). Here, EPAS1 is linked to nonpapillary renal cell carcinoma.